By Caroline Simson ( April 4, 2014, 8:36 PM EDT) -- Sanofi SA and its top executives allegedly misled investors about the potential success of its subsidiary's multiple sclerosis drug Lemtrada, causing shareholders to miss out on millions of dollars when the drug failed to receive regulatory approval, a complaint filed in New York federal court claims....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.